Literature DB >> 12837985

Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas.

João Cruz1, Jorge S Reis-Filho, Paula Silva, José Manuel Lopes.   

Abstract

OBJECTIVES: The c-met tyrosine-kinase receptor and its ligand hepatocyte growth factor are involved in cell survival, proliferation, motility, and invasion. Experimental data have suggested a putative role in melanomagenesis and progression of cutaneous malignant melanoma (CMM). We sought to evaluate c-met expression in a cohort of 62 primary CMM patients diagnosed and primarily treated at the same institution.
METHODS: Sixty-two cases of CMM were retrospectively retrieved from the archives of the Department of Pathology, Hospital São João, Porto, Portugal. All classical clinicopathological features were reviewed. Only those patients in whom representative paraffin blocks were available and the diagnosis of primary CMM was confirmed, and who were followed up after the primary diagnosis were included in the study. Immunohistochemistry for c-met was performed in 59 cases, and semiquantitatively and qualitatively (membranous and cytoplasmic, M+C, or cytoplasmic) evaluated. Statistical analysis was performed using chi(2), ANOVA and Kaplan-Meier/log-rank tests.
RESULTS: M+C pattern of c-met expression was significantly associated with presence of vertical growth phase (p = 0.0198), thick tumors (p = 0.0006), ulceration (p = 0.0386), high mitotic index (p = 0.0008), lymphatic (p = 0.0086) and vascular (p = 0.0080) invasion, and nodal (p = 0.0422) and combined (nodal and/or visceral) metastases (p = 0.0234). M+C pattern of c-met expression also proved to be a significant prognostic factor for overall survival in univariate analysis (p = 0.0125).
CONCLUSIONS: Our findings suggest that the pattern of c-met expression is a relevant prognostic factor for overall survival and is associated with more aggressive behavior of primary CMMs. Copyright 2003 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12837985     DOI: 10.1159/000071207

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  21 in total

Review 1.  Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?

Authors:  József Tímár; Balázs Gyorffy; Erzsébet Rásó
Journal:  Clin Exp Metastasis       Date:  2010-02-24       Impact factor: 5.150

Review 2.  The role of microRNAs and long non-coding RNAs in the pathology, diagnosis, and management of melanoma.

Authors:  Muhammad Nauman Aftab; Marcel E Dinger; Ranjan J Perera
Journal:  Arch Biochem Biophys       Date:  2014-07-24       Impact factor: 4.013

3.  The melanocyte differentiation program predisposes to metastasis after neoplastic transformation.

Authors:  Piyush B Gupta; Charlotte Kuperwasser; Jean-Philippe Brunet; Sridhar Ramaswamy; Wen-Lin Kuo; Joe W Gray; Stephen P Naber; Robert A Weinberg
Journal:  Nat Genet       Date:  2005-09-04       Impact factor: 38.330

4.  Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression.

Authors:  Beatriz A Walter; Maria Begnami; Vladimir A Valera; Mariarita Santi; Elisabeth J Rushing; Martha Quezado
Journal:  J Neurooncol       Date:  2010-07-10       Impact factor: 4.130

5.  Acid sphingomyelinase determines melanoma progression and metastatic behaviour via the microphtalmia-associated transcription factor signalling pathway.

Authors:  L Bizzozero; D Cazzato; D Cervia; E Assi; F Simbari; F Pagni; C De Palma; A Monno; C Verdelli; P R Querini; V Russo; E Clementi; C Perrotta
Journal:  Cell Death Differ       Date:  2013-12-06       Impact factor: 15.828

6.  Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.

Authors:  Yong Qin; Jason Roszik; Chandrani Chattopadhyay; Yuuri Hashimoto; Chengwen Liu; Zachary A Cooper; Jennifer A Wargo; Patrick Hwu; Suhendan Ekmekcioglu; Elizabeth A Grimm
Journal:  Mol Cancer Ther       Date:  2016-07-25       Impact factor: 6.261

Review 7.  Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis.

Authors:  Bonnie E Gould Rothberg; Michael B Bracken; David L Rimm
Journal:  J Natl Cancer Inst       Date:  2009-03-24       Impact factor: 13.506

8.  PAX3 and SOX10 activate MET receptor expression in melanoma.

Authors:  Joseph B Mascarenhas; Erica L Littlejohn; Rebecca J Wolsky; Kacey P Young; Maria Nelson; Ravi Salgia; Deborah Lang
Journal:  Pigment Cell Melanoma Res       Date:  2010-01-22       Impact factor: 4.693

9.  Predominant formation of heavily pigmented dermal melanocytomas resembling 'animal-type' melanomas in hepatocyte growth factor (C57BL/6 x C3H)F1 mice following neonatal UV irradiation.

Authors:  Scott R Florell; Joshua Thomas; Douglas Grossman
Journal:  J Cutan Pathol       Date:  2007-09       Impact factor: 1.587

10.  PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.

Authors:  Hal E Crosswell; Anindya Dasgupta; Carlos S Alvarado; Tanya Watt; James G Christensen; Pradip De; Donald L Durden; Harry W Findley
Journal:  BMC Cancer       Date:  2009-11-25       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.